- Biosion receives over $40 million
cash payment as upfront license fee and reimbursement for certain
development costs & drug product materials, and 19.9% shares of
common stock of Aclaris Therapeutics; additional regulatory and
sales milestone payments exceed $900M
with tiered single digit sales royalty
- Aclaris Therapeutics will be responsible for development and
commercialization of BSI-045B, a novel anti-TSLP monoclonal
antibody, and BSI-502, a novel bispecific antibody that is directed
against both TSLP and IL4R worldwide (excluding Greater China)
NEWARK,
Del. and NANJING,
China, Nov. 18,
2024 /PRNewswire/ -- Biosion, Inc. (Biosion), a
global R&D stage biotechnology company, today announced that it
has entered into an exclusive license agreement with Aclaris
Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding
Greater China) to BSI-045B, a
potential First-in-class, clinical-stage, novel anti-TSLP
monoclonal antibody, and BSI-502, a potential best-in-class,
pre-clinical stage, novel bispecific antibody that is directed
against both TSLP and IL4R.
Under the terms of the agreement, Biosion shall receive over
$40 million cash payment as upfront
license fee and reimbursement for certain development costs &
drug product materials. Biosion shall also receive 19.9% shares of
common stock of Aclaris Therapeutics. Additional regulatory and
sales milestone payments exceed $900M
with tiered low-to-mid single digit royalty based upon a percentage
of annual net sales.
"This transaction once again validates our proprietary antibody
discovery platforms, BSI-045B and BSI-502 demonstrate the power of
our discovery capabilities in generating potential first-in-class
and best-in-class therapeutics." said Mingjiu Chen, Ph.D.,
Founder and CEO of Biosion. "Together with our global partners
through the complementary expertise and resources, we hope to bring
more transformative medicines to patients worldwide."
"This transaction marks Biosion's ninth and tenth global
partnered programs under our
'discover-development-partnership' model," said
Anthony Yeh, Ph.D., Chief Strategy
Officer of Biosion. "This partnership accelerates the worldwide
clinical development of two key assets while securing the financial
resources necessary to advance our other innovative programs to IND
filings."
In a completed Phase 2a, single-arm, proof-of-concept trial in
the United States in 22 patients
with moderate to severe atopic dermatitis, BSI-045B was observed to
have a pharmacodynamic, safety and efficacy profile that could
position it as a potential best-in-class therapy. BSI-045B is also
being advanced in multiple Phase 2 studies in China by Biosion's regional partner, Chia Tai
Tianqing Pharmaceutical Group, Co., Ltd. (CTTQ), targeting both
severe asthma and chronic rhinosinusitis with nasal polyps,
accelerating the potential to show proof-of-concept across
additional indications.
"This strategic transaction brings together Biosion's innovative
programs with our development capabilities in immunology, and we
are excited to enhance our portfolio with these compelling assets,"
said Dr. Neal Walker, Interim CEO
and Chair of the Board of Directors of Aclaris. "We look forward to
further developing these assets in our quest to deliver exceptional
therapies for patients worldwide."
About BSI-045B
BSI-045B is a humanized anti-thymic stromal lymphopoietin (TSLP)
monoclonal antibody that specifically binds to human TSLP, blocking
its interaction with the receptor complex and disrupting signal
transduction. This mechanism prevents immune cells targeted by TSLP
from releasing proinflammatory cytokines. BSI-045B is currently in
clinical development, and its safety and efficacy have not been
evaluated by regulatory authorities.
About BSI-502
BSI-502 is a humanized anti-TSLP and anti-interleukin 4 receptor
(IL4R) bispecific antibody that blocks both the upstream TSLP
receptor signal transduction and downstream IL4R activation thereby
inhibiting this central proinflammatory pathway. BSI-502 is
currently in pre-clinical development, and its safety and efficacy
have not been evaluated by regulatory authorities.
About Biosion
Biosion is a global clinical-stage biotechnology company focused
on developing innovative antibody-based therapies to improve
outcomes for patients with immune and oncologic diseases.
Leveraging its proprietary technologies such as the
H³ antibody discovery platform, SynTracer® HT endocytosis
platform, and Flexibody® bispecific platform, Biosion creates
highly differentiated medicines to address significant unmet
medical needs worldwide. With its
"discover-development-partnership" model, the company has
forged 10 global collaborations, advancing seven clinical-stage
assets, including monoclonal antibodies, bispecific antibodies, and
antibody-drug conjugates. Biosion operates across the US,
China, and Australia. Learn more at
www.Biosion.com.
View original
content:https://www.prnewswire.com/news-releases/biosion-announces-exclusive-global-license-agreement-with-aclaris-therapeutics-on-two-potential-first-in-class-and-best-in-class-immunology-assets-302308547.html
SOURCE Biosion, Inc.
